Multikine: Phase III ongoing

Cel-Sci said an IDMC recommended for the second time continuation of an open-label, international Phase III trial of Multikine based on a review of safety data. The trial is comparing Multikine plus standard of care (SOC) vs. SOC alone in 880 patients. SOC comprises surgery plus radiotherapy or surgery plus concurrent radiochemotherapy. Following the review, Cel-Sci said it would expand the trial to include more clinical sites to accelerate enrollment. Multikine has Orphan Drug designation in the U.S. to treat SCCHN. ...